Bioventus launches osteoarthritis treatment in Taiwan
HOOFDDORP, The Netherlands, January 5, 2016
Bioventus, a leader in orthobiologic solutions, has launched Durolane, a single-injection joint-fluid osteoarthritis (OA) treatment based on a natural, safe and proven technology process called Nasha which yields stabilised hyaluronic acid (HA).
Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint, said a statement.
In Taiwan, Durolane is indicated for the treatment of mild to moderate (OA) of the knee, it said.
Tony Bihl, chief executive officer, Bioventus, said: “The combination of a leading OA solution like Durolane and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market.
“Orthobiologic solutions from Bioventus are now available in six countries in the Asia Pacific region and we plan to build on this as we continue our international expansion.”
Isabelle Levy-Unger, managing director - International, for Canada, Latin America and Asia Pacific, said: “In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopaedics.
“The company’s market coverage, relationships with key opinion leaders, along with its keen understanding of markets and trends made it the natural choice to help us introduce DUROLANE to patients with knee OA." - TradeArabia News Service
